Session II: Cancer of the Pancreas

Wednesday, June 28, 2023

13:45 – 17:35 CEST

Location:Auditorium A, Level 0

Chair(s)

Eileen O'Reilly, MD

Memorial Sloan Kettering Cancer Center
New York, United States
Eric Van Cutsem, MD, PhD

University Hospitals Leuven / KU Leuven
Leuven, Belgium

Presentations:

13:45 – 14:05 CEST

Hereditary Predisposition to Pancreatic Cancer & Surveillance of Patients with Hereditary Predisposition
Speaker: Talia Golan, MD – Sheba Medical Center
14:05 – 14:25 CEST

Diagnosis and Management of Premalignant Pancreatic Lesions - IPMN
Speaker: Alain Sauvanet – Hopital Beaujon, APHP, University Paris Cité
14:25 – 14:35 CEST

Flash: Laparoscopic vs Robotic Surgery
Speaker: Thilo Hackert – Dept. of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Germany
14:35 – 14:45 CEST

Flash: What is Resectable Pancreatic Cancer & Is There A Role for Complex Surgery – Arterial Resections
Speaker: Oliver Strobel, MD, MBA – Medical University of Vienna
14:45 – 14:55 CEST

Debate: Resectable Pancreatic Cancer: Neoadjuvant Chemotherapy in All Patients? - PRO
Debate Speaker: Teresa Macarulla, MD, PhD – Vall d’Hebrón University Hospital
14:55 – 15:05 CEST

Debate: Resectable Pancreatic Cancer: Neoadjuvant Chemotherapy in All Patients? - CON
Debate Speaker: Thomas T. Seufferlein, MD, PhD – Ulm University
15:05 – 15:15 CEST

Debate: Resectable Pancreatic Cancer: Neoadjuvant Chemotherapy in All Patients? - DISCUSSION
Panelist: Thilo Hackert – Dept. of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Germany
Panelist: Florence Huguet, Professor – Hôpital Tenon, AP-HP, Sorbonne Université
Panelist: Teresa Macarulla, MD, PhD – Vall d’Hebrón University Hospital
Panelist: Thomas T. Seufferlein, MD, PhD – Ulm University
15:15 – 15:25 CEST

Debate: Radiotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) - YES
Debate Speaker: Florence Huguet, Professor – Hôpital Tenon, AP-HP, Sorbonne Université
15:25 – 15:35 CEST

Debate: Radiotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) - NO
Debate Speaker: Philip A. Philip, MD, PhD, FRCP – Wayne State University School of Medicine/Henry Ford Health
15:35 – 15:45 CEST

Debate: Radiotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) - DISCUSSION
Panelist: Florence Huguet, Professor – Hôpital Tenon, AP-HP, Sorbonne Université
Panelist: Philip A. Philip, MD, PhD, FRCP – Wayne State University School of Medicine/Henry Ford Health
Panelist: Oliver Strobel, MD, MBA – Medical University of Vienna
16:15 – 16:25 CEST

Debate: Molecular Therapies in Pancreatic Ductal Adenocarcinoma: NGS for All or None - PRO
Debate Speaker: Philip A. Philip, MD, PhD, FRCP – Wayne State University School of Medicine/Henry Ford Health
16:25 – 16:35 CEST

Debate: Molecular Therapies in Pancreatic Ductal Adenocarcinoma: NGS for All or None - CON
Debate Speaker: Thierry Conroy, MD – institut de cancérologie de Lorraine
16:35 – 16:45 CEST

Debate: Molecular Therapies in Pancreatic Ductal Adenocarcinoma: NGS for All or None - DISCUSSION
Panelist: Philip A. Philip, MD, PhD, FRCP – Wayne State University School of Medicine/Henry Ford Health
Panelist: Thierry Conroy, MD – institut de cancérologie de Lorraine
16:45 – 16:55 CEST

O-1: Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients metastatic pancreatic ductal adenocarcinoma: sensitivity analysis of survival from the NAPOLI 3 trial
Abstract Presenter: Zev A. Wainberg, MD, Msc – UCLA School of Medicine
16:55 – 17:15 CEST

Current Standards & New Emerging Options in Metastatic Pancreatic Cancer
Speaker: Eileen M. O'Reilly, MD – Memorial Sloan Kettering Cancer Center
17:15 – 17:35 CEST

Thrombosis in GI Cancers: Biology; Prophylaxis in All Patients?
Speaker: Mario A. Dicato, MD – Luxembourg Medical Center